CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Publisher: La Merie Publishing
Pages: 80
Format: PDF
Product Line:
Brief Report
Product Line:
Target Pipeline
Product Code: LMBR0014
Release Date: November of 2016

700.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodkgina lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for targeted delivery of payloads by immunotherapeutics such as antibodies or engineered T-cells.

Monotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest efficacy results indicating the need for more effective payloads, but at the same time also providing development opportunities for new treatment modalities such as

  • Combination therapies;
  • Radioimmunotherapy (RIT);
  • Immunotoxins (IT);
  • Antibody-Dug Conjugates (ADC); and
  • Chimeric Antigen Receptor (CAR) T-Cells.

This report describes the profiles of 16 different specific and bispecifi anti-CD22 immunotherapeutics based on different treatment modalities. The most advanced molecules has been submitted for regulatory approval. Furthermore, the profiles of nine companies active in the development of anti-CD22 immunotherapeutics are presented. This report describes and analyzes the

  • Target Background & Scientific Rationale
  • Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
  • Competitive Landscape
  • Profiles of Anti-CD22 Immunotherapeutics
  • Profiles of Companies with CD22-Targeted Immunotherapeutics.

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Table of Contents

Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics

  • Naked antibodies;
  • Radioimmunotherapy (RIT);
  • Immunotoxins (IT);
  • Antibody-Dug Conjugates (ADC); and
  • Chimeric Antigen Receptor (CAR) T-Cells.

Profiles of Companies with CD22-Targeted Immunotherapeutics.
References

ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics

 



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top